Roche Holding AG (LON:0QQ6)
London
· Delayed Price · Currency is GBP · Price in CHF | Market Cap | 188.61B |
| Revenue (ttm) | 55.00B |
| Net Income (ttm) | 7.30B |
| Shares Out | n/a |
| EPS (ttm) | 9.09 |
| PE Ratio | 25.85 |
| Forward PE | n/a |
| Dividend | 8.49 (3.18%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 610 |
| Average Volume | 6,863 |
| Open | 267.40 |
| Previous Close | 269.40 |
| Day's Range | 265.40 - 268.80 |
| 52-Week Range | 236.00 - 317.40 |
| Beta | 0.14 |
| RSI | 38.95 |
| Earnings Date | Apr 25, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial numbers in CHF Financial StatementsNews
Roche: Forget Tariffs And Focus On The Positives -- There Are Many
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight
Omeros Corporation (NASDAQ: OMER) on Thursday established the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program focused on acute myeloid leukemia (AML) . AML is...
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
Zealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With Roche
The Danish biotech's recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed its potential.
Biocon shares rise over 3% as USFDA approves bevacizumab biosimilar Jobevne™ for cancer treatment
Shares of Biocon Ltd surged 3.07% to ₹315.70 in Friday’s early trade after its subsidiary, Biocon Biologics Ltd (BBL), secured approval from the U.S. Food and Drug Administration (USFDA) for its bevac...
Biocon Biologics gets FDA nod for Roche's bevacizumab biosimilar
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Global pharma shares plunge as Trump doubles down on tariff threat
Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain, and...
Trump teases targeted tariffs on overseas drug manufacturers
With the next set of White House–imposed tariffs just hours away from taking effect — including the attention-hogging 104% rate to be levied on products from China as they're imported into the U.S. — ...
Roche To Start Phase 3 Study For Alzheimer's Prospect This Year After New Data From Phase 2
Roche's trontinemab data showed dose-dependent amyloid reduction ... Full story available on Benzinga.com
Roche To Start Phase 3 Study For Alzheimer's Prospect This Year After New Data From Phase 2
Roche Holdings AG RHHBY on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer's and Parkinson's Diseases.
Sarepta, Roche seek to resume Elevidys trials
Roche: Consumers Aren't "Strong Enough" to Bear Tariffs
Cullen Roche says that markets are losing sight of the fact that things were “already dicey” economically even before tariffs. He calls the next 12-18 months “pretty worrisome.
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
In March, Sarepta Therapeutics, Inc. (NASDAQ: SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy. The ...
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
In March, Sarepta Therapeutics, Inc. SRPT shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.
Roche presents novel therapeutic and diagnostic advancements in Alzheimer's at AD/PD 2025
Basel, 3 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data were presented at the AD/PD 2025 International Conference on Alzheimer's and Parkinson's Diseases in Vienna, Aust...
Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer's at AD/PD 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data were presented at the AD/PD 2025 International Conferen...
Pharma tariff relief likely short-lived with sector-specific duties on the horizon
Pharmaceutical companies breathed a sigh of relief Wednesday after U.S. President Donald Trump revealed that they would not be subject to reciprocal tariffs — but that reprieve could prove fleeting. T...
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
Roche's MUSETTE trial found no additional benefit of ... Full story available on Benzinga.com
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
Roche Holdings AG RHHBY on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) intravenous (IV) infusion in adult patients with relapsing multiple sclerosis (RM...
IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche
TG Therapeutics rallied Wednesday after Roche's rival multiple sclerosis treatment, Ocrevus, missed its mark in a study.
TG Therapeutics rises after trial setback for high dose version of Roche’s MS drug
Roche fails in bid to increase dose of MS drug Ocrevus
Roche said on Wednesday that a trial testing higher doses of its multiple sclerosis drug Ocrevus did not show an efficacy benefit over the standard dose, a setback in a bid to further boost usage of t...
Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MUSETTE trial comparing a high dose of Ocrevus® (o...